Artificial intelligence is rapidly becoming the defining infrastructure layer of modern drug development, and clinical-stage oncology company Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself at the center of this shift. The California-based company has spent years building a proprietary AI platform and is now turning it into something more ambitious than a simple drug-discovery tool.
The most significant development to date came when Oncotelic announced the successful integration of approximately 28 million scientific abstracts into its PDAOAI platform. This massive data integration allows the platform to analyze vast amounts of biomedical literature, potentially accelerating the identification of novel drug targets and therapeutic candidates.
The broader market context makes Oncotelic's strategy worth taking seriously. The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and is projected to grow at a compound annual growth rate of roughly 26% through 2031, reaching over $10 billion. This growth underscores the increasing reliance on AI to streamline and enhance the drug development process.
Oncotelic's central technology, the PDAOAI platform, was designed from the outset to be more than a research accelerator for internal programs. By integrating such a vast repository of scientific knowledge, the company aims to create a platform that can out-innovate larger pharmaceutical companies. The move signals that small biotechs can compete with big pharma by leveraging advanced AI capabilities.
For more information on Oncotelic's latest news and updates, visit the company's newsroom at ibn.fm/OTLC.
